Search results
Showing 136 to 150 of 192 results for myocardial infarction
Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack
This indicator covers the percentage of patients diagnosed with hypertension (diagnosed on or after 1 April 2009) who are given lifestyle advice in the preceding 12 months for: smoking cessation, safe alcohol consumption and healthy diet. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM112
Lipid disorders: FH assessment and diagnosis (new readings) (IND261)
This indicator covers the percentage of patients with a total cholesterol reading in the preceding 12 months greater than 7.5 mmol/litre who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM245
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.
Lipid disorders: FH assessment and diagnosis (historical readings) (IND260)
This indicator covers the percentage of patients with a total cholesterol reading greater than 7.5 mmol/litre when aged 29 years or under, or greater than 9.0 mmol/litre when aged 30 years or over, who have been: diagnosed with secondary hyperlipidaemia, or clinically assessed for familial hypercholesterolaemia, or referred for assessment for familial hypercholesterolaemia, or genetically diagnosed with familial hypercholesterolaemia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM244
Helping to prevent winter deaths and illnesses associated with cold homes
A quick guide for home care managers on preventing deaths and illnesses associated with cold homes.
Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease....
The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)
NICE has developed a Medtech Innovation Briefing (MIB) on the AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation
The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)
NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Cardiovascular disease. Patient decision aid on should I take a statin?
What are heart disease and stroke? Heart disease includes heart attacks and angina. Heart attacks happen when the blood...
Evidence-based recommendations on DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography.
View recommendations for MTG60Show all sections